Skip to main content

Table 2 Post-treatment status of the patient

From: Thymalfasin therapy accelerates COVID-19 pneumonia rehabilitation through anti-inflammatory mechanisms

 

0 (n = 233)

1 (n = 105)

t/χ2

P

Treatment days

11.7 ± 4.10

10.4 ± 2.08

4.07

< 0.01

Critically ill or not

220/13

104/1

2.82

0.09

Time of negative conversion

9.88 ± 2.82

9.48 ± 2.22

1.40

0.16

WBC

7.14 ± 3.99

6.46 ± 1.65

2.2

0.02

WBC change

1.02 ± 4.14

1.52 ± 1.97

-1.51

0.13

LYM

1.15 ± 0.54

1.44 ± 0.55

-4.56

< 0.01

LYM change

0.29 ± 0.43

0.86 ± 0.57

-9.16

< 0.01

CRP

17.6 ± 20.7

12.8 ± 13.27

2.61

0.01

CRP change

-42.2 ± 48.44

-57.9 ± 38.82

3.19

0.0016

PCT

0.08 ± 0.19

0.088 ± 0.25

-0.27

0.79

PCT change

-0.12 ± 0.48

-0.11 ± 0.40

-0.243

0.80

Fever (yes/no)

(6/227)

(20/85)

2.78

0.01

listlessness(yes/no)

(19/214)

(35/70)

1.93

0.02

Inflammatory exudate area shown on lung CT (%)

5.8 ± 4.1

14.2 ± 5.6

4.32

0.03

  1. Treatment days: Thymalfasin group shorter than control group, LYM lymphocytes: elevated in both groups, and more pronounced in Thymalfasin group, CRP C-reactive protein: decreased in both groups, and more pronounced in Thymalfasin group